In This Section

Lindsey A. George, MD
Lindsey A. George
Tenure Assistant Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania

Dr. George's basic and clinical research interests are in the development of novel therapeutics for hemophilia. Her basic science laboratory studies the molecular basis of coagulation, and she is the principal investigator of ongoing hemophilia A and B gene therapy trials.

AddtoAny
Share:

Bio

Dr. George's basic and clinical research interests are in the development of novel therapeutics for hemophilia. Her basic science laboratory studies the molecular basis of coagulation with the goal of exploiting the biochemical basis of blood clotting for therapeutic translation. She is the principal investigator of ongoing hemophilia A and B gene therapy trials.

Education and Training

BS, Cornell University, 2004

MD, University at Buffalo School of Medicine, 2008

Pediatric Resident, Weill Cornell Medical College 2008-2011

Pediatric Chief Resident, Weill Cornell Medical College 2011-2012

Pediatric Hematology/Oncology fellowship, Children's Hospital of Philadelphia 2012-2015

Titles and Academic Titles

Tenure Assistant Professor of Pediatrics, Perelman School of Medicine, University of Pennsylvania

Member, Perelman Center for Cellular and Molecular Therapeutics

Attending Physician, Division of Hematology, Children's Hospital of Philadelphia

Professional Memberships

International Society of Thrombosis and Haemostasis World Federation of Hemophilia, 2013-

World Federation of Hemophilia, 2017-

American Society of Hematology, 2010-

American Society of Gene and Cell Therapy, 2015-

Hemostasis and Thrombosis Research Society, 2015-

Professional Awards

2017 Eberhard Mammen Young Investigator Award for Excellence in Thrombosis and Hemostasis, San Diego, CA

2018 Professor Heimburger Award in Hemostasis, Marburg, Germany

2019 National Top 10 Clinical/Translational Research Award, Clinical Research Forum, Washington, D.C.

2019 Scholar Award of the National Blood Foundation, Washington, D.C.

Publication Highlights

Wilhelm AR, Parsons N, Davidson RJ, Camire RM, George LA. In Vivo Hemostatic Significance of Activated Protein C in Factor VIIIa Regulation. Blood. 2019 Nov; 134 (Supplement 1): 93
Samelson-Jones BJ, Finn JD, George LA, Camire RM, Arruda VR1. Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity. JCI Insight. 2019 Jan; 5(14). PubMed PMID: 31219805
George LA, Sullivan SK, Giermasz G, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majuddar S, Teitel J, McGuinn CE, Ragni MV, Luk AY, Hu Di, Wright JF, Chen Y, Liu Y, Wachtel K, Winters A, Tiefenbacher S, Arruda VR, van der Loo JCM, Zelenaia O, Takefman D, Carr ME, Couto LB, Anguela XM, High KA. Hemophilia B Gene Therapy with a High Specific Activity Factor IX Variant. N Engl J Med. 2017 Jan; 377(23): 2215-2227. PubMed PMID: 29211678* Note: Published with accompanying editorial